Matteo Levisetti - 20 Feb 2024 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Chief Medical Officer
Signature
/s/ Matteo Levisetti by Colin Sandercock, attorney-in-fact
Issuer symbol
CUE
Transactions as of
20 Feb 2024
Transactions value $
$0
Form type
4
Filing time
22 Feb 2024, 16:00:07 UTC
Previous filing
25 Jul 2023
Next filing
08 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +25,000 $0 25,000 20 Feb 2024 Common Stock 25,000 $3.36 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 17, 2023 the Reporting Person was granted an option with vesting subject to the satisfaction of performance-based vesting criteria. The performance-based vesting criteria was deemed satisfied or waived on February 20, 2024 and these shares underlying the option vested in full.